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Abstract
Bitter molecules in humans are detected by ,25 G protein-coupled receptors (GPCRs). The lack of atomic resolution
structure for any of them is complicating an in depth understanding of the molecular mechanisms underlying bitter taste
perception. Here, we investigate the molecular determinants of the interaction of the TAS2R38 bitter taste receptor with its
agonists phenylthiocarbamide (PTC) and propylthiouracil (PROP). We use the recently developed hybrid Molecular
Mechanics/Coarse Grained (MM/CG) method tailored specifically for GPCRs. The method, through an extensive exploration
of the conformational space in the binding pocket, allows the identification of several residues important for agonist
binding that would have been very difficult to capture from the standard bioinformatics/docking approach. Our calculations
suggest that both agonists bind to Asn103, Phe197, Phe264 and Trp201, whilst they do not interact with the so-called extra
cellular loop 2, involved in cis-retinal binding in the GPCR rhodopsin. These predictions are consistent with data sets based
on more than 20 site-directed mutagenesis and functional calcium imaging experiments of TAS2R38. The method could be
readily used for other GPCRs for which experimental information is currently lacking.
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Introduction
Bitter taste perception prevents humans and other mammals
from ingesting toxic substances. The perception stems from the
binding of bitter molecules to ,25 specific G protein-coupled
receptors (GPCRs) referred to as taste 2 receptors (TAS2Rs) [1,2]
(Fig. S1). TAS2Rs are located in special subsets of taste receptor
cells [1–4]. They are able to detect multiple and diverse natural
and synthetic organic molecules [5].
The most widely characterized bitter receptor at the genetic
level is TAS2R38 [6,7]. Single nucleotide polymorphisms in the
TAS2R38 gene (GenBank: AY258597.1) cause ‘‘blindness’’ to its
agonists phenylthiocarbamide (PTC) and propylthiouracil (PROP)
(Chart S1) [6]. This constitutes a well-characterized human
genetic trait [7]. Indeed, in normal population, regardless of race,
age and gender, there are many subjects that were able to perceive
phenylthiocarbamide (PTC) and its related compounds, with the
N-C = S moiety, while many other subjects do not [8].
Experimental 3D structural information on TAS2R38, as on
any other bitter taste receptor, is lacking. Functional assays-
validated bioinformatics approaches, complemented with molec-
ular docking [9], have provided structural insights on agonist/
TAS2R38 interactions. A similar procedure has been used
successfully for other TAS2Rs [10–13]. The responses of the
different receptor mutants have been measured upon application
of increasing concentrations of agonists. If the EC50 value is larger
than that of the wild-type (WT), the receptor sensitivity is
impaired, whilst the contrary is true if the EC50 is lower. Higher
maximal signal amplitude usually may stand for improved
receptor activation relative to WT, whilst a lower one stands for
an impaired activation. These pieces of information have been
included in the model, providing insights in structure/function
relationships. In spite of these insights, the approach has clear
limitations in describing the active site cavity of the receptor.
Structural predictions of TAS2R38 (as of any other TAS2R) is
difficult because it shares a sequence identity with structural
templates of less than 20% [9]. Hence, the orientation of the side-
chains in the active site cavity is likely not to be correct.
Recently, we have developed a combined atomistic-coarse
grained approach [14] for structural predictions of agonist- and
antagonist- GPCR complexes, the Molecular Mechanics/Coarse-
Grained (MM/CG) molecular dynamics [15,16]. Here, the ligand,
the solvent surrounding it and the binding cavity are represented
with an atomistic force field, while the rest of the protein frame is
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described using a Go-like [17] CG representation (Fig. 1A). The
hydration is taken into account by including a sphere of water
molecules centred on the ligand (Fig. 1B). An interface (I region) is
defined between MM and CG regions that bridge the two different
resolution models. In this way, the number of degrees of freedom is
drastically reduced by up to 2 orders of magnitude [14]. This
allows the system to be equilibrated in much shorter time scale,
and it may be able to avoid artefacts caused by wrong orientations
of side-chains in loop and in helices far from the active site. We
have shown that 0.8 ms MM/CG simulations of a GPCR/inverse-
agonist complex for which the 3D X-ray structure is experimen-
tally available -the b2 adrenergic receptor/S-Carazolol (b2 AR/S-
Car)- could reproduce the results of full atomistic MD [14,18].
Importantly, the approach turns out to recover the orientation of
the S-Car ligand as in the X-ray structure irrespectively of its
initial orientation [14]. The MM/CG simulation took less than a
week on a 64 cpus PC cluster.
Here, we explore the capability of this approach to predict
structural determinants of TAS2R38. First, we show that ms-long
MM/CG simulations are capable to reproduce the structure of the
b2 AR/S-Car complex X-ray structure starting from a homology
model. The same setup applied to TAS2R38 structure in complex
with PTC and PROP turns out to be fairly consistent with as many
as 22 receptor mutants expressed for this work and tested for two
different agonists, providing insights on the interaction between a
bitter taste receptor and its agonists at an unprecedented level of
accuracy.
Results
Validation of the MM/CG Method for Homology Models
We have recently shown [14] that MM/CG calculations of b2
AR in complex with its ligand S-Car are in agreement with the
corresponding ones with all-atom MD on the same system [18].
The calculations are based on the X-ray structure of the complex
[19]. Here we further investigate the predicting power of the MM/
CG method using a homology model of the same complex
(Fig. 2A). The chosen template for building up the model of the b2
AR was the structure of squid rhodopsin (PDB id 2z73) [20]. It
displays a sequence identity of 20% with the target protein. This
value is within the range of the identities between the hTAS2R38
and its best templates. After 0.8 ms, the b2 AR structure in
complex with S-Car is similar to the X-ray structure (RMSD of the
Ca atoms 2 A˚, Fig. 2B). The interactions observed between the
ligand and the protein present in the X-ray structure are
reproduced with Ser5.42 and Asp3.32 side-chains forming H-
bonds with the agonists amino groups, and Asn7.39 present in the
ligand binding cavity (Fig. 2C–D) as it is in the X-ray structure.
Hence, MM/CG simulations on a homology-modelled structure
reproduce the ligand pose as in the X-ray structure [19], indicating
that our approach can be used in general for ligand/GPCR’s
complexes. The same procedure is next applied to the human
TAS2R38 receptor.
Bioinformatics- and MM/CG-based Structural Predictions
of TAS2R38
The predicted structural determinants of the protein, obtained
by homology modelling, are either the same as those of ref. [9]
(model A) or they are very similar except that they differ for the
ECL2 loop (model B, selected ligands-receptor distances in
Table 1). The latter points away from the binding cavity in B,
resembling the ‘open’ conformations found in the non-rhodopsin
templates (see Table S1). In contrast, in A, the ECL2 loop assumes
a conformation close to the putative binding cavity (The rest of the
folding domain is very similar to all the structures used as
templates). The volume of the cavities can be appreciated in the
Text S1 document and in Figure S3A and B. The structures of the
corresponding adducts with PTC and PROP (details in Text S1),
obtained by molecular docking (PTC/A, PTC/B, PROP/A and
PROP/B hereafter), underwent two different runs of 0.6 ms each
of MM/CG simulations [14] at room temperature. All adducts
appear to be equilibrated after ,0.1 ms, as shown by a plot of the
RMSD of the Ca atoms and of the agonists atoms as a function of
simulated time (Fig. S2). Although loop structure predictions are
well known not to be very accurate [21], we conclude that ECL2
points away from the binding cavity in PTC/B and PROP/B
complexes, and close to it in PTC/A and PROP/A. The PTC/A
Figure 1. Molecular Mechanics/Coarse-grained system set-up. A) Schematic representation of the regions defined in the MM/CG model. The
MM, I and CG regions are colored in green, orange, light blue, respectively. B) MM/CG representation of the hTAS2R38 receptor in complex with PTC.
Water molecules and residues belonging to the MM and I regions are represented as lines. The agonist atoms are represented as orange spheres. The
protein Ca atoms are represented in violet.
doi:10.1371/journal.pone.0064675.g001
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structure shows the ECL2 is close to the binding cavity, while in
PTC/B the ECL2 is located away from it and in contact with the
extracellular region. Three ECL2 residues, Asn179, Arg181 and
Asn183 form either direct contacts with the agonists or contribute
to shape the binding cavity in A but not in B (Fig. 3). Specifically,
at times Arg181, Asn183 interact with PTC sulphur atom, Asn179
interacts with PROP NH group, Thr180 with PROP oxygen
atom, and Arg181 with PROP sulphur atom (Fig. 3). This allows
us to discriminate between the models with the conformation A
from those with the conformation B. Indeed, we can predict that
mutations such as Asn179Ala/Val, Arg181Ala/Val and As-
n183Ala/Val do not affect agonist binding in PROP/B and
PTC/B complexes, whilst they will in the case of PTC/A and
PROP/A. Here we performed functional assays on these mutant
variants following ref. [9]. The EC50 values of the mutants turn
out to be similar to those of WT (Fig. 4A–F and Table 2). This
leads us to discard the A models (The A models turn out not to be
consistent with several other mutations performed by us - data not
shown, then rhodopsin-like models were not considered). Thus,
from now on therefore we consider only the PROP/B and PTC/
B complexes.
Models Validation
In PTC/B, the agonist sulphur atom forms H-bonds with
Asn103 side-chain (Table 1 and Fig. 3). It also forms an H-bond
with Tyr193 side-chain. Ser260 side-chain forms H-bonds to
Trp201 side-chain. The PTC ring forms hydrophobic interactions
with Phe197, with Trp201 and Phe264. In PROP/B, the agonist
sulphur atom forms H-bonds to Asn103 NH2 group. The agonist
oxygen atom forms H-bond to Ser260 side-chain. The PROP ring
forms hydrophobic contacts with Trp201, Phe264 and Phe197.
These hydrophobic residues, together with Tyr193, shape the
binding cavity.
Functional assays have been reported by us for nine mutants of
TAS2R38 in complex with PTC complex [9]. Those experiments
were repeated here (Fig. 5A–D) and extended to the TAS2R38/
PROP complex (Fig. 5E–H). The results turned out to be very
similar for both agonists (Table 2, Fig. 5A–H): (i) The EC50 values
of TAS2R38-Met100Ala (Fig. 5D), -Trp99Ala and -Trp99Val
(Fig. 5B and F) are similar to those of WT. Those of the
TAS2R38-Met100Val mutant turned out to be larger than WT
(Fig. 5H). This may indicate that Met100 is close to the binding
cavity and the presence of a valine residue may occlude the
binding cavity. Consistently with these results, our simulations
suggest that Met100 and Trp99 do not interact with the agonists
but contribute to the shaping of the binding cavity. (ii) The EC50
Figure 2. b2 AR in complex with the S-Car ligand. A) S-Car binding site of the central structure of the only cluster of the MM/CG simulations.
This cluster represent 100% of the conformations of the adduct. B) RMSD of the Ca atoms plotted as a function of time in the MM/CG simulations. C–
D) Distribution of agonist-protein H-bonds in the MM/CG simulations of the b2 AR/S-Car complex based on the X-ray structure [14] (black line) and
on an homology model (violet line, this work).
doi:10.1371/journal.pone.0064675.g002
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values of TAS2R38-Asn103Ala and -Asn103Val (Fig. 5A and E)
turn out to be larger than that of WT. Asn103 side-chain forms an
H-bond with both agonists in our simulations. Hence, their
mutations to Ala and Val should impair these interactions,
consistently with the experimental results. (iii) The EC50 of
TAS2R38-Ser259Val is larger than that of WT, whilst -Ser259Ala
is similar to WT (Fig. 5C and G). Our simulations suggest that
Ser259 is close to the agonists without any direct interaction. This
is also consistent with experiment: the fact that the EC50 value
increases for the Val mutants may be due to the presence of a
bulkier residue in position 259, which with its higher steric
hindrance could impair the binding. Instead, Ala, which is similar-
in-size with Ser, is expected not to greatly affect the binding.
Next, we expressed new mutations, which may affect key
receptor/agonists interactions and/or receptor binding cavity
shape according to our MM/CG calculations (Table 1 and Fig. 3).
These include: (i) The TAS2R38-Asn103Asp mutation, which
should disrupt the Asn103/agonists sulphur atom H-bond. This
causes a repulsive electrostatic interaction between Asp and the
partially negatively charged sulphur atom of both agonists. This
mutation should therefore severely impair binding (Fig. 6A and F
and Table 2). Consistent with this hypothesis, the EC50 values of
the mutant turn out to be much larger than those of the WT for
both the agonists. (ii) The TAS2R38-Phe197Val mutation, which
should affect Phe197 p-p stacking interactions with both agonists.
Fairly consistently, the EC50 value of TAS2R38-Phe197Val
turned out to be larger than that of WT upon PROP application
(Fig. 6B and G). The EC50 value of the mutant turned out also to
be larger, but not statistically significant, upon PTC application.
This leads us to the suggestion that Phe197 forms stronger
interactions with PROP than with PTC. (iii) The TAS2R38-
Phe264Ala and -Phe264Val mutations, which should disrupt
Phe264 p-p stacking interactions with both agonists. The mutation
to Ala may further affect the binding cavity shape because of the
small size of this residue. Consistent with this prediction, the EC50
of the mutants turned out to be larger than that of the WT (Fig. 6C
and H). (iv) The TAS2R38-Trp201Leu mutation, should disrupt
the Trp201 p-p stacking interactions with both agonists. Consis-
Table 1. Selected MM/CG distances (in Angstrom) in the
central structure of the main clusters of the PTC/B and PROP/B
adducts.
Distance PTC/B
Asn103-NH2 – PTC-S 3.1
Ser260-OH – Trp201-HN 2.5
Tyr193-HO – PTC-S 1.9
Phe197Ring – PTCRing 6.5
Phe264Ring – PTCRing 3.4
Trp201Ring – PTCRing 5.5
Trp99Ring – PTCRing 6.1
Met100side chain – PTCring 8.9
Distance PROP/B
Asn103-NH2 - PROP-S 3.0
Ser260-HO – PROP-O 1.6
Phe197 Ring – PROPRing 6.3
Phe264 Ring – PROPRing 4.5
Trp201 Ring – PROPRing 5.2
Trp99 Ring – PROPRing 8.3
Met100side chain – PROPring 7.1
doi:10.1371/journal.pone.0064675.t001
Figure 3. Central structures of PTC/A - PROP/A and PTC/B - PROP/B main clusters emerging from our MM/CG simulations. Residues
forming mostly or exclusively hydrophobic contacts with the agonists (Met100, Phe264, Phe197, Trp99, Trp201, Tyr193) are colored in green, pink,
orange, light violet, purple, yellow, respectively. The agonists are shown in ball-and-sticks representation and they are colored by atom type. The
ECL2 loop interacts with the binding site only in the A complexes. It is shown in red cartoon. Selected distances for Asn179, Thr180, Arg181 and
Asn183 residues in the ECL2 loop are shown for PTC/A and PROP/A.
doi:10.1371/journal.pone.0064675.g003
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tently, this mutation produced a severely impaired activation upon
PTC application and an almost failed activation upon PROP
application (Fig. 6D and I). (v) The TAS2R38-Trp201Phe mutant
might affect the p-p stacking interactions (with both the agonists)
due to the intrinsic difference between the two residues, and also
disrupt the H-bond with Ser260 observed in the PTC adduct. The
latter could play a role in shaping the binding cavity (Fig. 3). The
EC50 of the adduct with PTC is larger than that of WT (Fig. 6D
and I). Upon PROP application, we observe an almost complete
loss of function of the receptor. (vi) The TAS2R38-Ser260 residues
Figure 4. Dose-response curves. Dose-response curves of TAS2R38 wild type and mutants after stimulation with increasing PTC and PROP
concentrations (0 to 1000 mM). Each point corresponds to the mean 6 standard deviation. The mean is calculated from at least three independent
experiments. A–C) PTC application, D–F) PROP application.
doi:10.1371/journal.pone.0064675.g004
Agonist Binding to TASR38 Bitter Taste Receptor
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64675
may play a role for shaping the binding cavity (it interacts with
Trp201 in the adduct with PTC with as described in (v)) and/or
for substrate binding (it interact with PROP). To address this issue,
we investigate here the Val and Ala mutants in the position 260.
We find that the EC50 values of Ser260Val mutant are larger than
those of WT for both agonists, and those of TAS2R38-Ser260Ala
are similar to those of WT (Fig. 6E and J). These data suggest that
Ser260 participates in shaping the cavity and it may not be
involved in interactions with the agonists.
Discussion
We have presented a computational study of the TAS2R38
receptor in complex with its agonists PTC and PROP (Chart S1).
We have used our recently developed hybrid MM/CG approach
tailored for GPCRs to predict the structural determinants of the
adducts. The method turned out to reproduce the interactions
between the b2 AR with its ligand S-Car, even if the MM/CG
calculations are based on a homology model. The subsequent
MM/CG-based calculations of the hTAS2R38 complexes (based
on structures obtained by homology modelling and molecular
docking) have been tested against a pool of 22 molecular biology
data (Table 2).
The calculations, validated by experimental evidence provided
here and in ref. [9], show that the agonists interact Asn103,
Phe197, Phe264 and Trp201. This prediction could not be made
based on just our homology models and molecular docking
structures (data not shown).
According to our modelling, Asn103 forms an H-bond with the
agonists sulphur atom (Fig. 7). Asn103 corresponding position
(3.36 according Ballesteros-Weinstein numbering [22]) play a role
for ligand binding and/or for defining the binding cavity in other
human bitter taste receptors, including hTAS2R46 [10]),
hTAS2R31/R44, hTAS2R43 [23] and hTAS2R16 [11]
(Table 3). It may do so in another GPCR, the 5-HT2A receptor
[24]. In this receptor, the agonist 5-hydroxytryptamine, may form
an H-bond with the side-chain of Ser3.36 (Ser159), consistent with
the fact that the Ser3.36Ala mutation affects agonist binding.
Several aromatic residues including the highly conserved Trp99
(Figure S1 and Table 3) and Phe264 shape the agonists binding
cavity in both complexes. This supports the hypothesis [10] that
the binding cavities of bitter taste receptors are similar for different
agonists. Some of them might do so even across different receptors
of the family. We suggest this based on the fact that Trp99
corresponding position in hTAS2R31 (Trp88) also shapes the
binding cavity in that receptor [23] (Table 3).
Ser260 may contribute to shape the binding cavity of the
receptor. The corresponding position of Ser260 (6.52 according to
Ballesteros-Weinstein numbering [22]) might form hydrophobic
interactions with salicin agonists of hTAS2R16 (Phe240 in [11])
and an H-bond with strychnine agonist in hTAS2R46 (Tyr241 in
[10]). Hence, this position might be important for receptor
function across several members of the bitter taste family.
The ECL2 loop consists of non-conserved residues across the
family (Fig. S1) [25]. It is located relatively far from the binding
site. It does not form any interaction with the agonists. [19,26].
This is a common feature of all GPCRs for which X-ray structural
information is available other than rhodopsin [25,27]. Because
ECL2 displays a highly conserved N-glycosylation site [26] one has
to exercise care for any implications of these findings for the
function of the receptor in in vivo conditions.
Responses to PROP and PTC of the same mutant variants
sometimes are different (Table 2) in both maximal signal
amplitude and in EC50 values. Indeed, while TAS2R38-Trp99
mutant variants show higher maximal amplitude upon PROP
application than upon PTC application, TAS2R38-Met100,
Phe197 and Ser260 show different behaviour upon PROP or
PTC application, indicating a different role of the residues in
binding of a specific ligand. Thus, our data support the hypothesis
[10] that different agonists bind to similar but not identical binding
cavities. Probably, some crucial residues are involved in binding of
several different agonists, i.e. Asn103, and they also are quite well
conserved in the family, whereas other different residues are
directly interacting with different agonist. Hence, although several
residues (Asn103, Phe197, Trp201 and Phe264) interact with both
agonists, our results point out that the different response of the two
agonists is due to a small but still significant difference in the
binding cavities.
Receptor Activation
Differences in maximal signal amplitude (MSAs) of the mutants
investigated here may reflect differences on the receptor activation
mechanism. In this section, we discuss changes in MSAs, along
with bioinformatics arguments, to gain insights into the possible
role of receptors residues for its activation. We start our discussion
Table 2. Experimental EC50 and maximum activity values
towards PTC and PROP obtained for WT TAS2R38 and
selected mutants.
Variant Agonist
PTC PROP
EC50 (uM) Max act EC50 (uM) Max act
WT 2.5 (3) 0.43 (0.47) 2.17 0.44
Trp99Ala 1.2 (4.25) 0.14 (0.25) 1.8 0.59
Trp99Val 1.8 (2.7) 0.28 (1.12) 5, 0.93
Met100Ala 4.1 (3) 0.72 (1.01) 1.2 0.77
Met100Val 21.2* (10) 0.51 (0.79) 1.8 0.42
Asn103Ala 6.6* (8) 0.21 (0.38) 8.7* 0.65
Asn103Val 6.9* (15) 0.09 (0.09) 9.1* 0.41
Asn103Asp – 0.06 23.8* 0.13
Asn179Ala 4.4 0.34 4.9 0.32
Asn179Val 4.9 0.29 5 0.30
Arg181Ala 2.2 0.26 4.3 0.26
Arg181Val 4.5 0.17 7.5 0.19
Asn183Ala 4.2 0.36 5.3 0.32
Asn183Val 2.5 0.44 3.1 0.40
Phe197Val 4.3 0.06 9.9* 0.12
Trp201Leu – 0.25 – 0.02
Trp201Phe 21* 0.14 – 0.05
Ser259Ala 5.7 (5.4) 0.55 (0.42) 2.9 0.45
Ser259Val 99* (27) 0.02 (0.04) 21.8* 0.18
Ser260Ala 1.41 0.21 1.14 0.45
Ser260Val 9.8* 0.03 6.8* 0.09
Phe264Ala – 0,06 – 0,06
Phe264Val 12.4* 0.06 25.9* 0.24
*Value statistically different from WT , Estimated value, curve close to
saturation. WT and the mutants already investigated in ref. [9] are in bold-face.
For those, we report the values of ref. [9] in brackets.
doi:10.1371/journal.pone.0064675.t002
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Figure 5. Dose-response curves. Dose-response curves of TAS2R38 wild type and mutants after stimulation with increasing PTC and PROP
concentrations (0 to 1000 mM). Each point corresponds to the mean 6 standard deviation. The mean is calculated from at least three independent
experiments. A–D) PTC application, E–H) PROP application.
doi:10.1371/journal.pone.0064675.g005
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Figure 6. Dose-response curves. Dose-response curves of TAS2R38 wild type and mutants after stimulation with increasing PTC and PROP
concentrations (0 to 1000 mM). Each point corresponds to the mean 6 standard deviation. The mean is calculated from at least three independent
experiments. A-E) PTC application, F-J) PROP application.
doi:10.1371/journal.pone.0064675.g006
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with two highly conserved residues, Trp99 and Asn103 (Fig. S1).
The first, according to our modelling, does not interact directly to
the agonists, whilst the second does (Fig. 7). The MSAs of the
mutants involving the two positions differ from those of WT for
both agonists (Fig. 4–6). Hence, we suggest for these positions to be
important for the activation of this receptor and, because of the
high conservation of these residues, maybe for other members of
the family. At present, it is difficult to suggest any mechanistic role
for these residues. Phe197, Trp201 (on TM5) and Phe264 (on
TM6) are instead highly variable residues in the family (Fig. S1).
The MSAs of their mutants are very different than those of WT,
suggesting a role for receptor activation also for these residues. We
suggest that some of the mutations may affect stacking interactions
formed by these aromatic residues, which in turn are important for
activation with the PROP and PTC agonists.
We next focus on the TAS2R38 naturally polymorphic
positions (49, 262, and 296), which lead to impairment of receptor
activity [6,7]. Ala262 and Val296 are located in TM6 and TM7,
respectively. Val296 is far away from the binding cavity and
Ala262, although closer is not pointing to it or interacting with the
agonists (Fig. S4). Hence, differently to what claimed in ref [28],
residues in the two positions, Ala262 and Val296, might be
involved in the transduction mechanism rather than in ligand
binding. Position 49 in the models is located in a loop region (IC1)
far away form the putative binding cavity and due to the
difficulties in loop modelling at the present stage, it is impossible to
hypothesize a role in the activation mechanisms of the receptor.
In conclusion the protocol described here, which includes MM/
CG simulations on homology models and experiments, could be
applied to different members of the bitter taste receptors as well as
from the GPCR superfamily. The code, along with the MM/CG
trajectories as well as the homology models resulting from this
research, are freely available upon request.
Materials and Methods
Biocomputing
We generated structural models of TAS2R38 in the following
steps, as in [9]: (i) Identifying all human bitter taste receptors from
the Uniprot database (http://www.uniprot.org/), (ii) aligning the
sequence of the proteins identified in (i) using Promals [29] (Fig.
S1, SI). (iii) The aligned sequences from point (ii) were funnelled to
the HHpred web server (http://toolkit.tuebingen.mpg.de/
hhpred). (iv) Retrieving the sequences of the templates and their
Figure 7. Agonists binding. Binding of PTC and PROP to the TAS2R38 bitter receptor as emerging from MM/CG simulations and experiments.
Residues forming hydrophobic interactions and H-bonds with the agonists are indicated in blue and red, respectively. Residues shaping the cavities
are in black color. The ECL2 loop does not interact directly with the agonists.
doi:10.1371/journal.pone.0064675.g007
Table 3. Analysis of the positions mutated in this work that were also mutated in other members of the bitter receptors family.
Position in TAS2R38 Effect in TAS2R38 Position in other TAS2 receptors Effect in other TAS2 receptors
Ans103 Directly interacting with the agonist Asn92 (R46) [10] Interacting with agonist
Asn89 (R16) [11] H-bond with agonist
Asn92 (R31/R44)) [23] Direct interaction with agonist/shaping
binding cavity
Asn92 (R43/R61) [23] Critical role in activation
Ser260 Interacting with the agonist or with Trp201 Phe240 (R16) [11] Indirect participation in binding
Ser259 Not interacting but shaping the binding cavity Tyr241 (R46) [10] H-bond with agonist
Trp99 Not interacting but shaping binding cavity Trp88 (R31/R44) [23] Direct interaction with agonist/shaping
binding cavity
Met100 Not interacting but shaping the binding cavity Glu86 (R16) [11] H-bond with agonist
In column 3, the receptor name is indicated between parentheses.
doi:10.1371/journal.pone.0064675.t003
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corresponding structures. Some of them have been already
included in ref. [9] (highlighted in yellow in Table S1) (v)
Constructing 200 models of TAS2R38 based on the alignment in
(iii) and the 3D structures of the templates in (iv), that is, all the
GPCRs with known structure. The Modeller9v3 program was
used [30]. The representative of the two most populated clusters
extracted from the model structural ensemble (A and B, see
Results Section) turned out to represent 70% of the conforma-
tional ensemble, according to the clustering algorithm of ref. [31].
They were very similar one to the other except for the extracellular
loop ECL2. (vi) Generating models of the PTC/TAS2R38
complex in A conformation (PTC/A hereafter), PTC/TAS2R38
in B conformation (PTC/B), PROP/TAS2R38 in A conformation
(PROP/A), PROP/TAS2R38 in B conformation (PROP/B). We
docked phenylthiocarbamide (PTC) and propylthiouracil (PROP,
Fig. 3) on A and B using the Haddock program [32]. Asn103 binds
to PTC, and hence probably to PROP, because PROP is
structurally not too dissimilar to PTC (Fig. 3). Hence, it was
defined as an ‘active’ residue in the docking procedure of PTC/A,
PTC/B, PROP/A, PROP/B [32]. Trp99, Met100, Ser259 were
shown to shape the binding cavity [9]. They were defined as
‘passive’ residues in PTC/A, PTC/B, PROP/A, PROP/B. The
200 top complexes for each of those (according to the Haddock’s
scoring function [32]) underwent energy minimization in explicit
water, using Haddock [32]. The resulting structures were clustered
using the algorithm in ref. [31]. (vii) The four top complexes were
chosen as the ones satisfying all the active and passive restraints
and with lower energy values as from Haddock scoring function.
They underwent two replicas of 0.6 ms molecular mechanics/
coarse-grained MM/CG molecular dynamics simulations [14,15].
The complexes were split in a MM part, which includes the
GPCR agonist (or inverse agonist) and the residues in the binding
cavity (Fig. S2, SI), in a CG part, containing the protein frame and
in an interface region (I), defined between the MM and CG
regions. Hydration at the active site was accounted by including a
15 A˚ droplet of water molecules around the MM region. The
presence of the lipid bilayer was taken into account introducing a
wall located at 2.0 A˚ from the proteins Ca atoms. In particular, b2
AR.S-Car and TAS2R38 were encapsulated in a ,31 A˚ thick
implicit membrane. Two planar walls coincide with the height of
the lipid heads, two hemispheric walls cap the extracellular and
cytoplasmic ends of the protein. The last wall (‘membrane wall’)
follows the initial shape of the interface between protein and
membrane. Details on the MM/CG methodology can be found in
reference [14]. The proteins were partitioned in the MM and GC
regions. For b2-AR.S-Car, the first consists of residues 79–82, 86,
109 to 118, 164–165, 193–195, 199–208, 282, 286, 289–290, 293,
308, 311–316, and the second is given by the rest of the protein.
For TAS2R38, the first consists in residues 14–23, 70–101, 103–
104, 151–164, 187, 189, 193–204, 258–268 and 277–287, and the
second the rest of the protein. The MM and the I regions were
described with the GROMOS 96 force field [33]. RESP charges
[34] were derived for the agonists (PTC and PROP), using
structures optimized with HF-6-31G*, obtained with Gaussian03
[33]. Bonded parameters were obtained using the PRODRG
server [35]. Water is described with the SPC force field [36]. The
CG part is described using a Go-like potential [14,17]. We used a
cutoff of 16 A˚ for electrostatics, Van der Waals and Go-like
interactions. Residues included in the I region are determined as
the residues at a distance shorter or equal than 6 A˚ from the MM
boundary. The SHAKE algorithm was used to keep fixed the
distance of bonds containing hydrogen(s) [37]. The simulations
were performed at a constant temperature (300 K). The
thermostat in stochastic dynamics was controlled by setting the
inverse friction constant at a value of 0.4 ps. Once obtained, the
trajectories of each replica corresponding to each of the complexes
were joint and analysed performing a clustering analysis. For this
purpose, all the protein backbone was aligned and later the
conformations were clustered according to the position of the
ligand. A 1 A˚ cut-off was used to group the structures in the same
cluster.
Experiments
Site-directed mutagenesis. TAS2R38 mutants were ob-
tained by site-directed mutagenesis PCR using mutagenesis
overlapping primers and TAS2R38-PAV variant cDNA cloned
into a pcDNA5/FRT plasmid (Invitrogen) as template. For the list
of used oligonucleotides, refer to Table S2. The subsequent PCR-
mediated recombination using CMV forward primer, located
upstream of the cDNA sequence, and BGH reverse primer,
located downstream of the cDNA sequence was performed to join
the overlapping mutant fragments. The mutant cDNA sequences
were digested with EcoRI and NotI restriction enzymes, to be
cloned into a previously digested pcDNA5/FRT. The plasmid
presented an amino terminal export tag corresponding to the first
45 amino acids of rat somatostatin receptor 3 and a carboxy
terminal HSV tag [6,38,39]. The resulting mutant cDNA
constructs were sequenced to confirm their integrity [39].
Immunocytochemistry
The different mutant variants, as well as the TAS2R38-PAV
variant, were transiently transfected with Lipofectamine2000
(Invitrogen) in HEK 293T cells stably expressing the chimeric G
protein subunit Ga16gust44, very effective in coupling with bitter
taste receptors [40] [41]. HEK 293T cells were seeded on poly-D-
lysine coated coverslips and transfected with the different
TAS2R38 variants. Cells were washed with 37uC warm PBS
24 hr after transfection and incubated on ice for 1 hr. Later, they
were incubated on ice with biotin-labelled Concanavalin A
(Molecular Probes) for plasma membrane staining and fixed and
permeabilised with aceton-methanol 1:1 solution. Blocking was
done using 5% horse serum in PBS and antibody incubation was
performed over night at 4uC with 1:15000 mouse anti-HSV
primary antibody (Novagen). Secondary antibody incubation
included both 1:1000 Streptavidin Alexa Fluor633 to label plasma
membrane and 1:1000 Alexa488-conjugated anti-mouse IgG
(Molecular Probes) to label receptors (in 5% horse serum PBS),
for 1 hr at room temperature. Coverslips were mounted in Dako
mounting medium and analysed with a Leica confocal microscope
[6] [39].
Calcium Imaging Experiments
The different mutant variants, as well as the TAS2R38-PAV
variant, were transiently transfected with Lipofectamine2000
(Invitrogen) in HEK 293T cells stably expressing the chimeric G
protein subunit Ga16gust44. [3,40] 24 hours after transfection,
cells were loaded with Ca2+ sensitive Fluo4-AM dye, washed 3
times in C1 buffer (130 mM NaCl, 5 mM KCl, 10 mM Na-
Hepes, 2 mM CaCl2 and 10 m M Glucose, pH 7.4) and changes
in intracellular Ca2+ concentration upon agonist solution applica-
tion were recorded, at least 3 times independently for each mutant
variant, using a fluorometric imaging plate reader FLIPRTETRA
(Molecular Devices). Agonists were dissolved into C1 buffer in a
range of 0–1000 mM concentration. Experiments with previously
reported mutant variants upon PTC application [9] were repeated
for the present article in order to obtain fully comparable results.
Positive (TAS2R38-PAV variant) and negative (mock transfected)
controls were performed.
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Supporting Information
Figure S1 Alignment of the human bitter taste receptors
sequences family. These were retrieved from the Uniprot
database (http://www.uniprot.org/). The multiple sequence
alignment was carried out using the program Promals [29]. Green
columns correspond to the naturally polymorphic residues Pro49,
Ala262 and Val296. Red columns comprise residues: Trp99,
Met100, and Ser260. Blue columns indicate residues: Asn103,
Phe197, Trp201, Ser259 and Phe264. Finally the grey region
indicates the poorly conserved ECL2.
(TIF)
Figure S2 Two independent MM/CG simulations were
carried out for PTC/A, PTC/B, PROP/A and PROP/B.
Here we plot the RMSD of the Ca atoms of the four complexes as
a function of time for both simulations (red and black continuous
curves). Part of the ECL2 (residues 168 to 178) is very mobile in
one of the simulations of PROP/B, causing an increase of the
RMSD values (continuous red curve). However, it does not
interact at all with the agonist. The RMSDs of the protein
excluding residues 168 to 178 is indeed not too dissimilar to that of
the overall RMSD (dotted red line).
(TIF)
Figure S3 Largest cavities of models A and B identified
using Fpocket [42,43].
(TIFF)
Figure S4 Location of three major naturally polymor-
phic positions. Residues Ala262(blue), Val296(red) and Pro49(-
green) in the central structure of the principal clusters found in the
MM/CG simulation of PTC/B (left) and PROP/B (right). Val296
and Pro49 belong to the CG region, thus only the Ca atom is
shown. The positions of PTC and PROP agonists after the
docking are shown in cyan and yellow, respectively.
(TIFF)
Table S1 List of the GPCRs for which X-ray structures
are available. Their corresponding PDB codes, co-crystallized
ligands, species and resolution values are indicated. The structures
used in our previous work are highlighted in yellow [9].
(DOC)
Table S2 List of oligonucleotides used in site-directed
mutagenesis.
(DOC)
Text S1 Supporting information. Ligand binding cavity
volume calculations (calculated using the program FPocket
[42,43]). Molecular docking results
(DOC)
Chart S1 Chemical structures of the TAS2R38 ligands
used in the present work.
(TIF)
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